CBD Genetic Variants

CBD Genetic Variants

Introduction

Corticobasal Degeneration (CBD) is a heterogeneous neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena. Pathologically, CBD is characterized by tau-positive inclusions in [neurons](/entities/neurons) and glia, with 4R tau isoforms predominating. Genetic studies have identified MAPT (microtubule-associated protein tau) as the major genetic contributor to CBD risk, with the H1 haplotype being the primary risk factor and specific mutations causing familial cases.

Overview

CBD shows significant clinical and pathological overlap with other tauopathies:

• MAPT H1 haplotype: Major risk factor[@genotypephenotype]
• Specific MAPT mutations: Cause familial CBD presentations[@medical]
• Overlap genes: Shared risk with PSP, FTLD-Tau, and PD
• Other genes: Reported associations with DCTN, TGM6

Major Genetic Variants

MAPT H1 Haplotype

The MAPT H1 haplotype is strongly associated with CBD:

• Prevalence: >95% of CBD patients carry H1/H1 genotype
• Risk: H1/H1 increases CBD risk by 3-8 fold
• Mechanism: Altered tau isoform expression (increased 4R tau)

The H1 haplotype encompasses multiple risk SNPs:

• rs242557
• rs1800547
• rs2471738

MAPT Mutations in CBD

Several MAPT mutations cause CBD or CBD-like phenotypes:

P301L Mutation

The most well-known mutation causing CBD phenotypes:

...

CBD Genetic Variants

Introduction

Corticobasal Degeneration (CBD) is a heterogeneous neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena. Pathologically, CBD is characterized by tau-positive inclusions in [neurons](/entities/neurons) and glia, with 4R tau isoforms predominating. Genetic studies have identified MAPT (microtubule-associated protein tau) as the major genetic contributor to CBD risk, with the H1 haplotype being the primary risk factor and specific mutations causing familial cases.

Overview

CBD shows significant clinical and pathological overlap with other tauopathies:

• MAPT H1 haplotype: Major risk factor[@genotypephenotype]
• Specific MAPT mutations: Cause familial CBD presentations[@medical]
• Overlap genes: Shared risk with PSP, FTLD-Tau, and PD
• Other genes: Reported associations with DCTN, TGM6

Major Genetic Variants

MAPT H1 Haplotype

The MAPT H1 haplotype is strongly associated with CBD:

• Prevalence: >95% of CBD patients carry H1/H1 genotype
• Risk: H1/H1 increases CBD risk by 3-8 fold
• Mechanism: Altered tau isoform expression (increased 4R tau)

The H1 haplotype encompasses multiple risk SNPs:

• rs242557
• rs1800547
• rs2471738

MAPT Mutations in CBD

Several MAPT mutations cause CBD or CBD-like phenotypes:

P301L Mutation

The most well-known mutation causing CBD phenotypes:

• Inheritance: Autosomal dominant
• Penetrance: ~90% by age 65
• Phenotype: Classic CBD with prominent cortical symptoms
• Mechanism: Promotes tau aggregation, reduces microtubule binding

P301S Mutation

Reported in families with CBD features:

• Phenotype: Progressive aphasia and parkinsonism
• Mechanism: Similar to P301L

ΔN296 (Exon 10 Splicing)

Affects alternative splicing of exon 10:

• Effect: Increases 4R tau isoform
• Phenotype: CBD or PSP phenotype

R5L and Other Variants

• R5L: Rare variant associated with CBD in some families
• K369I: Reported in families with CBD features
• S305I: Affects exon 10 splicing

DCTN (Dynactin) Variants

DCTN encodes the p150 subunit of dynactin, involved in axonal transport:

• Common variant: p.G59D (autosomal dominant)
• Phenotype: Lower limb-onset parkinsonism with CBD features
• Mechanism: Impaired axonal transport

TGM6 (Transglutaminase 6)

Variants in TGM6 have been associated with CBD:

• Function: Cross-linking enzyme in neurons
• Mechanism: May affect protein aggregation
• Evidence: GWAS and family studies

Other Genetic Risk Factors

Shared Risk with Other Tauopathies

CBD shares genetic risk factors with:

• Progressive Supranuclear Palsy (PSP): MAPT H1 haplotype
• Frontotemporal Dementia with Tauopathy (FTLD-Tau): MAPT mutations
• Parkinson's Disease (PD): Some shared loci

Genome-Wide Association Studies

GWAS has identified:

• MAPT: Strongest signal
• TMEM106B: Also associated with FTLD
• GRN: Related to [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology

Disease Mechanisms

Tau Dysfunction in CBD

The genetic variants in MAPT lead to tau pathology:

Isoform imbalance: 4R tau overexpression from H1 haplotype

Hyperphosphorylation: Abnormal tau phosphorylation

Aggregation: Formation of tau filaments

Neuronal loss: Cortical and basal ganglia degeneration

Molecular Pathways

• Microtubule dysfunction: Loss of tau's microtubule-stabilizing function
• Axonal transport impairment: Affected by tau pathology
• Synaptic dysfunction: Early synaptic changes
• Glial involvement: Astrocyte and [microglia](/cell-types/microglia-neuroinflammation) activation

Pathological Overlap

CBD shows pathological overlap with:

• PSP (4R tau inclusions)
• FTLD-Tau (frontotemporal atrophy patterns)
• PD (in some cases, [alpha-synuclein](/proteins/alpha-synuclein) co-pathology)

Clinical Implications

Genetic Testing

Genetic testing for CBD is considered in:

• Early-onset patients (<60 years)
• Patients with family history
• Atypical presentations with cortical features

Testing typically includes:

• MAPT haplotype analysis
• Targeted MAPT mutation screening
• DCTN analysis if indicated

Genetic Counseling

• Autosomal dominant inheritance for mutations
• Variable expressivity
• Importance for family screening

Therapeutic Implications

Tau-targeted therapies:

• Anti-tau antibodies
• Tau aggregation inhibitors
• Kinase inhibitors

Gene therapy approaches:

• MAPT silencing via AAV
• Modulation of splicing factors

Symptomatic treatments:

• Limited response to dopaminergic therapy
• Physical/occupational therapy
• Speech therapy for dysarthria

See Also

• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [MAPT Gene](/genes/mapt)
• [Tau Protein](/proteins/tau)
• [Atypical Parkinsonism Genetic Variants](/diseases/atypical-parkinsonism-genetic-variants)
• [Tauopathies](/mechanisms/tauopathies)

Background

The study of Cbd Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Related NeuroWiki Pages

Disease Pages

• [Corticobasal Degeneration](/diseases/corticobasal-degeneration) — Primary disease page
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Related 4R tauopathy
• [Primary Age-Related Tauopathy](/diseases/primary-age-related-tauopathy) — Related tauopathy
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Common co-occurrence
• [Parkinson's Disease](/diseases/parkinsons-disease) — Lewy body comorbidity
• [FTLD-Tau](/diseases/frontotemporal-lobar-degeneration-tau) — Tauopathy spectrum

Gene & Protein Pages

• [MAPT Gene](/genes/mapt) — Major risk gene
• [MAPT Protein](/proteins/mapt-protein) — Tau protein
• [DCTN Gene](/genes/dctn1) — Dynactin, CBD association
• [TGM6 Gene](/genes/tgm6) — Transglutaminase 6
• [4R Tau](/proteins/tau) — Isoform predominating in CBD

Cell Type Pages

• [Cortical Neurons in CBD](/cell-types/cortical-neurons-cbd) — Affected neurons
• [Basal Ganglia Neurons](/cell-types/basal-ganglia-neurons) — Motor circuitry
• [Substantia Nigra in CBD](/cell-types/substantia-nigra-cbd) — Dopaminergic loss

Mechanism Pages

• [Tauopathy Mechanisms](/mechanisms/tauopathy) — 4R tau pathology
• [CBD Pathway](/mechanisms/cbd-pathway) — Disease mechanism
• [Axonal Transport Defects](/mechanisms/axonal-transport) — Neuronal dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation) — Glial involvement

Biomarker Pages

• [Tau PET in CBS/PSP](/biomarkers/tau-pet-cbs-psp) — Imaging biomarker
• [MRI Atrophy Patterns in CBS/PSP](/biomarkers/mri-atrophy-cbs-psp) — Structural MRI
• [DTI White Matter Changes in CBS/PSP](/biomarkers/dti-white-matter-cbs-psp) — White matter imaging

Treatment Pages

• [CBD Treatment Overview](/therapeutics/cortico-basal-degeneration) — Treatment options
• [CBD/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan) — Management guide
• [CBD/PSP Rehabilitation](/therapeutics/cbs-psp-rehabilitation-guide) — Physical therapy
• [Clinical Trials for CBD](/therapeutics/cbs-psp-clinical-trials-guide) — Trial information

Research Resources

• [CBD Investment Landscape](/investment/corticobasal_degeneration) — Research funding

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Adjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies.](https://pubmed.ncbi.nlm.nih.gov/41630268/) (2026 Jan 30) - Medicine
• [Genotype-Phenotype Correlations of COL2A1 and COL11A1 Patients.](https://pubmed.ncbi.nlm.nih.gov/40930209/) (2026 Jan) - American journal of ophthalmology
• [Medical Marijuana and Treatment Personalization: The Role of Genetics and Epigenetics in Response to THC and CBD.](https://pubmed.ncbi.nlm.nih.gov/41465160/) (2025 Dec 12) - Genes
• [Genome-wide association study and HLA genotyping for beryllium disease susceptibility in a European descent population.](https://pubmed.ncbi.nlm.nih.gov/41075949/) (2025 Nov 5) - Gene
• [Population-scale gene-based analysis of whole-genome sequencing provides insights into metabolic health.](https://pubmed.ncbi.nlm.nih.gov/41073786/) (2025 Oct) - Nature genetics

References